immunoglobulin superfamily member 9BGenealiases: LINC00947 · MIR4697HG
Q-omics provides the consensus-scored IGSF9B profile across patient tissues and cancer cell-line models. IGSF9B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, IGSF9B is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, IGSF9B RNA expression shows 18,668 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, THCA, and UVM as cancer lineages where IGSF9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGSF9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGSF9B survival associations across molecular data types. IGSF9B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGSF9B RNA expression–survival associations across cancer types. High IGSF9B expression shows unfavorable associations in THCA, KIRP and UCEC, but favorable associations in LUAD, ACC and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for IGSF9B RNA expression.
This table summarizes IGSF9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for IGSF9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGSF9B shows lower tumor expression in THCA, BLCA and UCEC and higher tumor expression in HNSC, KICH and LUAD. The THCA box plot shows higher IGSF9B RNA expression in normal versus tumor tissue (log2 FC = −1.231, t-test p < 0.001).
This table shows molecular features associated with IGSF9B in patient tissues and cancer cell lines. In patient samples, IGSF9B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGSF9B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
